What is the recommended dose and duration of ceftazidime for an 87-year-old male with recurrent urinary tract infections (UTIs) caused by Pseudomonas aeruginosa, who is susceptible to ceftazidime and has a ciprofloxacin (Cipro) allergy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftazidime Dosing for Pseudomonas UTI in Elderly Patient with Cipro Allergy

For an 87-year-old male with recurrent UTI caused by Pseudomonas aeruginosa who is susceptible to ceftazidime and has a ciprofloxacin allergy, the recommended dose is 2 grams IV every 8 hours for 10-14 days.

Dosing Considerations

  • The FDA-approved dosing for ceftazidime for complicated urinary tract infections is 500 mg IV every 8-12 hours 1
  • However, for Pseudomonas infections specifically, higher doses are recommended: 2 grams IV every 8 hours 2, 1
  • For elderly patients, renal function assessment is crucial as ceftazidime is primarily excreted by glomerular filtration 1
  • If creatinine clearance is reduced, dose adjustment is necessary according to the following schedule 1:
    • CrCl 50-31 mL/min: 1 gram every 12 hours
    • CrCl 30-16 mL/min: 1 gram every 24 hours
    • CrCl 15-6 mL/min: 500 mg every 24 hours
    • CrCl <5 mL/min: 500 mg every 48 hours

Duration of Therapy

  • For complicated UTIs caused by Pseudomonas aeruginosa, a treatment course of 10-14 days is recommended 2
  • Treatment should continue for at least 2 days after signs and symptoms of infection have disappeared 1
  • In recurrent UTIs, especially in elderly patients, the full 14-day course is often preferred to ensure complete eradication 2

Administration Considerations

  • Ceftazidime should be administered intravenously for systemic Pseudomonas infections 1
  • Intermittent bolus dosing may result in variable plasma concentrations, particularly in critically ill patients 3
  • Consider a loading dose of 2 grams followed by maintenance dosing based on renal function 1
  • Continuous infusion may be an alternative in some cases (100-150 mg/kg/day) but is generally reserved for specific situations 2

Monitoring Recommendations

  • Monitor renal function regularly during treatment, especially in elderly patients 1
  • Assess clinical response within 72 hours of initiating therapy 2
  • Consider follow-up urine cultures after completion of therapy to confirm eradication 2
  • Watch for potential adverse effects including hypersensitivity reactions, Clostridium difficile-associated diarrhea, and superinfections 4

Important Clinical Considerations

  • Ceftazidime has excellent activity against Pseudomonas aeruginosa and is an appropriate choice when ciprofloxacin cannot be used due to allergy 2, 1
  • In elderly patients, the risk of adverse effects may be higher due to decreased renal function and potential drug interactions 1
  • Ensure adequate hydration during treatment to maintain renal function and help flush the urinary tract 2
  • For patients with recurrent UTIs, consider urological evaluation to identify any underlying structural abnormalities once the acute infection resolves 5

Common Pitfalls to Avoid

  • Underdosing ceftazidime for Pseudomonas infections can lead to treatment failure and development of resistance 3
  • Failing to adjust dosage based on renal function can lead to toxicity in elderly patients 1
  • Not completing the full course of antibiotics may result in recurrence of infection 2
  • Inadequate monitoring of clinical response and potential adverse effects 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Intermittent bolus dosing of ceftazidime in critically ill patients.

The Journal of antimicrobial chemotherapy, 1997

Research

Treatment of recurrent complicated urinary tract infections in children with vesicoureteral reflux.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 2016

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.